New Risk • Jun 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.72m market cap, or US$5.33m). Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Sep 30
Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025 Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025. Board Change • Feb 04
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. 공시 • Oct 04
Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024 Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024. Board Change • Oct 02
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. New Risk • Aug 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Shares are highly illiquid. Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$710k revenue, or US$483k). Market cap is less than US$10m (AU$9.26m market cap, or US$6.30m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding). Board Change • Jun 21
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • May 21
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. New Risk • Feb 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$97k). Market cap is less than US$10m (AU$11.1m market cap, or US$7.22m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). Board Change • Feb 14
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Nov 29
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. 공시 • Nov 23
Bio-Gene Technology Limited Approves the Election of Alex Ding as Director Bio-Gene Technology Limited at its AGM held on November 23, 2023, approved the election of Mr. Alex Ding as a Director. 공시 • Oct 30
Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company Secretary Bio-Gene Technology Limited announced the appointment of Mr. Roger McPherson as joint Company Secretary on an interim basis. Roger has more than 25 years' experience in senior finance roles in a wide variety of industries. His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office. In the past, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Bio- Gene, Patrys Limited, TPI Enterprises Ltd. and eChoice Home Loans. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities. He has over 20 years of biotechnology and pharmaceutical experience. In addition to his role with Bio-Gene, Roger also provides CFO services to other unlisted entities. Board Change • Oct 30
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. 공시 • Oct 02
Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023 Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time. New Risk • Sep 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$95k). Minor Risks Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Market cap is less than US$100m (AU$17.6m market cap, or US$11.2m). Board Change • Sep 05
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. New Risk • Aug 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$681k revenue, or US$458k). Minor Risk Market cap is less than US$100m (AU$15.1m market cap, or US$10.2m). Reported Earnings • Aug 01
Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022) Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022). Board Change • Jul 10
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Alex Huong was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. New Risk • Jun 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 4.6% per year over the past 5 years. Revenue is less than US$1m (AU$97k revenue, or US$65k). Market cap is less than US$10m (AU$14.3m market cap, or US$9.58m). Board Change • Jun 22
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Alex Huong was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. 공시 • May 12
Bio-Gene Technology Limited Announces Changes to the Board Bio-Gene Technology Limited announced the following changes to the Board and management: Due to significantly increased commitments associated with his other roles, Mr. Robert Klupacs has advised the Board that he will be retiring from the Board effective 31 July 2023. Before that time he will continue to act as Chair of the Company, and will be heavily involved in strategic negotiations for the company alongside the Bio- Gene management team. Robert joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017, before becoming a Non-Executive Director in January 2018. Robert became Chair of the Company in November 2019. The Company also announces that Mr. Alex Ding and Mr. Chris Ramsay will join the Bio-Gene Board, effective immediately. Alex Ding was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list. Christopher Ramsay has over 30 years experience in the agricultural sector across business development, marketing and broader agronomy. He has held leadership roles in BASF and Nufarm among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and principal director of a boutique agribusiness consulting firm. Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness. Board Change • Apr 26
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 28
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 24
First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022) First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Board Change • Jan 05
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 10
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 18
Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021) Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 22
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 28
Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020) Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020). Breakeven Date Change • Jul 27
Forecast to breakeven in 2024 The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule. Breakeven Date Change • Jul 03
Forecast to breakeven in 2024 The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule. Reported Earnings • Feb 19
First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020) First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. 
